Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is shown to be an effective therapeutic option for somatostatin-expressing neuroendocrine neoplasms. Some concerns are raised over safety of this modality in patients with a history of regional chemoembolization and radionuclide hepatic embolization (CRHE) and is cause of reluctance among some physicians for suggesting 177Lu-DOTATATE in this patient population.Methods
We retrospectively reviewed 143 patients with somatostatin-expressing neuroendocrine tumors who underwent 177Lu-DOTATATE PRRT. Statistical analysis was performed on effect of 177Lu-DOTATATE in patients with and without prior CRHE using resampling procedures and correlation coefficient (r).Results
Proportion of toxicity in patients with and without CRHE was comparable (P = 0.246). No statistically significant correlation (r) found between any toxicity and prior CRHE (r = −0.3 to −0.03) or time elapsed between embolization and the first cycle of PRRT (r = −0.59 to 0.17). Following PRRT, 76.5% of patients with CRHE experienced benefit (partial response + stable disease), whereas 23.4% experienced progressive disease. Patients with CRHE showed more stable disease (P = 0.048) and less progressive disease (P = 0.046) following PRRT compared with no CRHE. The CRHE and no-CRHE status shared same probability for developing partial response/complete response following PRRT (P = 0.50).Conclusions
Treatment with 177Lu-DOTATATE did not show clinically or statistically significant toxicity in CRHE patients regardless of frequency of embolization or time interval between embolization and first PRRT. Results suggested a statistically significant higher response rate in patients with a history of CRHE. A prior history of CRHE is not a contraindication to subsequent PRRT.